News & Updates

Four cycles of neoadjuvant chemotherapy (NACT) results in better pathological response and survival than three NACT cycles in patients with muscle invasive bladder cancer, reveals a recent study.

Induction with ixazomib-based regimens appear to be insufficient for older patients newly diagnosed multiple myeloma who are ineligible for transplantation, achieving an unsatisfactory progression-free survival (PFS) rate, reports a recent study.

Intracorporeal urinary diversion (ICUD) is associated with similar postoperative complication rates, reduced blood loss and shorter hospitalization vs extracorporeal urinary diversion (ECUD) in patients undergoing robotic-assisted radical cystectomy (RARC) for localized bladder cancer, data from the Asian RARC Consortium registry have shown.

Vaccination against SARS-CoV-2 appears to lead to favourable outcomes in multiple myeloma (MM) patients who contract the coronavirus disease 2019 (COVID-19), even in the presence of negative prognostic factors, a recent study has found.

Adipose tissue radiodensity is significantly associated with the risk of death in patients with nonmetastatic colorectal cancer (CRC), independent of body mass index and changes in body weight, results of a study have shown.

In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Non-Hodgkin lymphoma (NHL), particularly follicular and mature T/NK-cell lymphomas, is more likely to develop among patients with breast cancer, a recent study has found. Moreover, such risk is greater among those who had been treated with hormone therapy.

The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.